August 1, 2018
Authored and Edited by Jessica L.A. Marks; Shana K. Cyr, Ph.D.
On June 7, 2018, USPTO Deputy Commissioner for Patent Examination Procedure Robert W. Bahr issued a Memorandum on Recent Subject Matter Eligibility Decision: Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals.
The Memorandum reviews the Federal Circuit’s April 13, 2018, decision in the Vanda case, which held claims directed to methods of treatment that included “arguably conventional genotyping and treatment steps” to be patent eligible. Memorandum at 2. The Memorandum states that the USPTO’s subject matter eligibility guidance is consistent with the Vanda decision: “(1) ‘method of treatment’ claims that practically apply natural relationships should be considered patent eligible under Step 2A of the USPTO’s subject matter eligibility guidance; and (2) it is not necessary for ‘method of treatment’ claims that practically apply natural relationships to include nonroutine or unconventional steps to be considered patent eligible under 35 U.S.C. § 101.” Memorandum at 2-3.
Readers are encouraged to read the Memorandum, also available on USPTO’s website.
Food and Drug Administration (FDA), FDA Guidance, United States Patent and Trademark Office (USPTO), patent-eligible, drugs, combination product
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Webinar
June 13, 2024
Webinar
Conference
4th Spring Pharmaceutical Synchrotron X-Ray Powder Diffraction Workshop
June 10-11, 2024
Basel
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Conference
16th Annual Practitioners’ Think Tank on ITC Litigation & Enforcement
May 29-30, 2024
Washington
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
INCONTESTABLE® Blog
S.D.Tex. Finds Tequila Marks CASA AZUL and CLASE AZUL Not Confusingly Similar
May 17, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.